5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Laurus Labs Ltd.

•
lauruslabs.comBSE: 540222NSE: LAURUSLABS
Market Cap₹ 1,06,460 Cr.
Current Price
High / Low₹ 1,982 / 823
Stock P/E97.4
Book Value₹ 104
Price to Book10.15
Dividend Yield0.10 %
ROCE18.2 %
ROE18.3 %
Face Value₹ 2

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2014 • Pharmaceuticals: 99.0% • Infosystems: 1.0%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company has consistently been profitable over the last 5 years
  • Latest quarter profit grew 123.9% YoY, showing strong momentum
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 2.05x)
  • Institutional investors have been accumulating - FII+DII up 4.1pp
  • Company comfortably covers its interest (7.9x coverage)
  • Company has a consistent dividend-paying track record

CONS

  • Company has a low return on capital employed of 11.7%
  • Company has delivered a poor profit growth of -2.0% over past five years
  • Stock is trading at 10.2x its book value
  • Company has delivered a poor sales growth of 7.2% over past five years
  • Expensive relative to growth - PEG of 25.9
  • Though reporting repeated profits, the company pays out little dividend (12.1%)

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTYM150MOMNTM50NIFTY ALPHA 50NIFTY PHARMANIFTY500MOMENTM50NIFTYLARGEMIDCAP250
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.BIOCON390.95128.6363712.890.13136.8053.364336.0010.893.2619.54
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
1,1821,2241,1951,4401,1951,2241,4151,7201,5701,6531,7781,8122,026
1,0151,0371,0141,1981,0241,0451,1301,3001,1871,2501,2981,2991,554
Operating Profit167188181241171178285421382403480512472
OPM %14.11%15.34%15.18%16.77%14.33%14.57%20.15%24.45%24.35%24.39%27.00%28.27%23.30%
422193595910276129
Interest39425150495358565240394042
Depreciation919398102106108106110117120121122124
Profit before Tax4154351071823131312224270327361481
Tax %30.01%27.04%27.30%29.78%33.86%22.31%30.66%25.12%28.16%28.17%22.49%21.99%24.79%
Net Profit0000132093233162194252282362
0.460.690.431.400.230.371.714.343.023.614.675.176.81

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
1,9052,0562,2922,8324,8144,9366,0415,0415,5546,8137,270
1,4971,6431,9362,2673,2633,5134,4484,2634,4995,0355,402
Operating Profit4084133565651,5511,4221,5927781,0551,7781,868
OPM %21.40%20.10%15.53%19.94%32.22%28.82%26.36%15.42%19.00%26.09%25.69%
33291662415626755554
Interest10080889068102165183216171161
Depreciation106125164187205251324385430480487
Profit before Tax2352371202941,3011,0841,1092364841,1821,439
Tax %18.65%29.40%21.70%13.06%24.39%23.20%28.16%28.83%26.82%24.71%24.20%
Net Profit191168942559848327971683548901,091
EPS20.7815.768.804.7918.2815.3514.642.936.6416.46—
Dividend Payout %8.42%9.49%17.03%10.47%10.91%12.99%13.73%27.34%18.06%12.15%—

COMPOUNDED SALES GROWTH

10 Years:
14%
5 Years:
7%
3 Years:
4%

COMPOUNDED PROFIT GROWTH

10 Years:
21%
5 Years:
-2%
3 Years:
4%

STOCK PRICE CAGR

10 Years:
—
5 Years:
25%
3 Years:
72%
1 Year:
120%

RETURN ON EQUITY

10 Years:
18%
5 Years:
16%
3 Years:
10%
Last Year:
18%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2026

May 8

₹ 0.60

Rs.1.2000 per share(60%)Interim Dividend

2025

Oct 31

₹ 0.40

Rs.0.8000 per share(40%)Interim Dividend

2025

May 9

₹ 0.40

Rs.0.8000 per share(40%)Interim Dividend

2024

Nov 6

₹ 0.20

Rs.0.4000 per share(20%)Interim Dividend

2024

May 8

₹ 0.20

Rs.0.4000 per share(20%)Interim Dividend

2023

Nov 2

₹ 0.20

Rs.0.4000 per share(20%)Interim Dividend

2023

May 10

₹ 0.60

Rs.1.2000 per share(60%)Interim Dividend

2022

Nov 3

₹ 0.40

Rs.0.8000 per share(40%)Interim Dividend

2022

May 10

₹ 0.60

Rs.1.2000 per share (60%) Second Interim Dividend

2021

Nov 17

₹ 0.40

Rs.0.8000 per share(40%)Interim Dividend

2021

May 11

₹ 0.40

Rs.0.8000 per share (40%) Third Interim Dividend

2021

Feb 8

₹ 0.20

Re.0.4000 per share (20%) Second Interim Dividend

2020

Nov 10

₹ 0.40

Rs.0.8000 per share(40%)Interim Dividend

2018

Jun 28

₹ 0.15

Rs.1.5000 per share(15%)Dividend

2017

Jul 6

₹ 0.15

Rs.1.5000 per share(15%)Dividend

2020

Apr 30

₹ 0.10

Rs.1.0000 per share(10%)Final Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital106106106107107107108108108108
Minority Interest000038115130131
1,2191,3711,4471,6582,4853,2353,9183,9824,3395,167
9051,0451,0961,1341,6351,9222,2262,3982,7702,776
Trade Payables2633124886161,1798767111,0519581,252
911301401613428206878441,0301,077
Total Liabilities2,5842,9643,2783,6765,7516,9687,6608,3879,33610,511
1,2301,4811,6291,7262,1712,6523,4093,8904,1234,371
Capital Work in Progress14316311067362813551423458773
333333150124233309
5095856829051,5751,7601,6851,8451,9372,342
00000001,6632,0072,155
Cash & Bank4332487648142144114
6947298519721,5911,6351,918300433447
Total Assets2,5842,9643,2783,6765,7516,9687,6608,3879,33610,511

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
3824043233879621,0931,2796666021,624
Cash from Investing-289-384-253-221-941-914-996-822-682-1,089
Cash from Financing-5442-45-12825530-2725039-525
-1010-14727-2993-4110

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
27.1827.1827.6227.6227.5927.5927.4927.4927.47
25.6726.0825.5625.5125.7026.1726.5225.8228.00
13.5613.0512.7411.7811.9411.7212.4213.9613.73
Government0.000.000.000.000.000.000.000.000.00
33.5933.6934.0835.0934.7834.5133.5632.7130.79

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-10
Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-10 - Laurus Labs Limited has informed the Exchange about Schedule of meet

2026-08-31
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-31 - Laurus Labs Limited has informed the Exchange about Schedule of meet

2026-08-12
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-12 - Laurus Labs Limited has informed the Exchange about Schedule of meet

2026-08-10
General Updates

2026-08-10 - Laurus Labs Limited has informed the Exchange about Intimation of ESG Score given by NSE Sustainability Ratings and Analytics Limited

2026-07-30
Analysts/Institutional Investor Meet/Con. Call Updates

2026-07-30 - Laurus Labs Limited has informed the Exchange about Transcript

2026-07-27
General Updates

2026-07-27 - Laurus Labs Limited has informed the Exchange about Allotment of ESOP

2026-07-25
General Updates

2026-07-25 - Laurus Labs Limited has informed the Exchange about Update On Composite Scheme of Arrangement

2026-07-25
Copy of Newspaper Publication

2026-07-25 - Laurus Labs Limited has informed the Exchange about Copy of Newspaper Publication

2026-07-24
Analysts/Institutional Investor Meet/Con. Call Updates

2026-07-24 - Laurus Labs Limited has informed the Exchange about Link of Recording

News

Recent coverage and analyst commentary for LAURUSLABS

Loading news…

🤖

AI Stock Analyst

Laurus Labs Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login